Inhibrx Biosciences, Inc.
ozekibart (INBRX-109)
conventional chondrosarcoma
Resolved
97days ago
Catalyst readout · Apr 1, 2026
What's at stake
A key catalyst for ozekibart (INBRX-109) (conventional chondrosarcoma) is expected Apr 1, 2026.
Primary source
· SEC 8-K
verified 13h ago
“Additionally, in April 2026, we submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ozekibart in conventional chondrosarcoma;”